Compare SHG & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHG | IQV |
|---|---|---|
| Founded | 1982 | 1982 |
| Country | South Korea | United States |
| Employees | N/A | 93000 |
| Industry | Major Banks | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.9B | 28.6B |
| IPO Year | 2003 | 2013 |
| Metric | SHG | IQV |
|---|---|---|
| Price | $67.39 | $167.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $227.13 |
| AVG Volume (30 Days) | 263.8K | ★ 1.3M |
| Earning Date | 04-24-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.11% | N/A |
| EPS Growth | N/A | ★ 4.67 |
| EPS | N/A | ★ 7.84 |
| Revenue | N/A | ★ $9,739,000,000.00 |
| Revenue This Year | $4.86 | $6.78 |
| Revenue Next Year | $3.66 | $5.88 |
| P/E Ratio | ★ $9.79 | $21.55 |
| Revenue Growth | N/A | ★ 41.60 |
| 52 Week Low | $31.86 | $134.65 |
| 52 Week High | $73.40 | $247.05 |
| Indicator | SHG | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 65.96 | 43.50 |
| Support Level | $58.10 | $159.42 |
| Resistance Level | $73.40 | $170.89 |
| Average True Range (ATR) | 1.41 | 6.26 |
| MACD | 0.76 | 1.03 |
| Stochastic Oscillator | 96.10 | 30.45 |
Shinhan Financial Group Co Ltd is a Korean banking group. Along with its subsidiaries the company provides, comprehensive financial services which consist of commercial banking services, credit card services, securities services, insurance, credit services, and asset management services, including securities investment trust management, investment advisory, call transaction, domestic and foreign private equity fund business, and other services. The majority of the revenue is generated from its Banking business which includes retail, corporate, international, and other banking services the company offers.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.